Cigna PBM Express Scripts to remove Humira from many formularies
by
Contributor since / Followers
Contributor since / Followers
2 months ago
JHVEPhoto/iStock Editorial via Getty Images
- AbbVie’s Humira (adalimumab) will be taken off the formulary lists of many Cigna (NYSE:CI) health care plans in 2025 in favor of cheaper biosimilar version.
- Members next year can get Simlandi from Teva (TEVA) and Alvotech (ALVO), Cyltezo from Boehringer Ingelheim, or an unbranded version of Hyrimoz from Novartis (NVS) division Sandoz.
- Despite the introduction of many Humira biosimilars, AbbVie still controls most of the market for adalimumab thanks to deals made with pharmacy benefit managers, according to Reuters.
- In January, CVS Health said that its Caremark PBM would remove Humira from its commercial formularies on April 1.